Cellectis announced that four new members joined Cellectis’ Clinical Advisory Board (CAB). The CAB serves as a strategic resource to Cellectis as the company enters the clinical development of allogeneic CAR T immunotherapies lead by its wholly owned product candidate, UCART123. New Board Members Include Professors John Gribben, Koen van Besien, Kanti Rai and Catherine Thieblemont.